Precigen

Helen Sabzevari, Ph.D., President and CEO

Oct. 11 | 3:30pm | Ecolab Life Sciences Ballroom 

Germantown, MD

(NASDAQ: PGEN)

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.

www.precigen.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions